KYMERA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.32 USD | -1.92% |
|
+0.66% | +38.73% |
Presenter SpeechVikram Purohit (Analysts)Great. Good morning. Welcome, everyone. Let us go ahe...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâs own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platformâs capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.
Calendar
2024-05-28
- TD Cowen Oncology Innovation Summit
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
35.32
USD
Average target price
50.8
USD
Spread / Average Target
+43.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.73% | 2.21B | |
| +44.48% | 54.04B | |
| +43.57% | 41.96B | |
| -0.86% | 41.92B | |
| -7.59% | 28.35B | |
| +12.30% | 26.35B | |
| -21.83% | 19B | |
| +7.15% | 13B | |
| +29.40% | 12.28B | |
| +25.15% | 12.19B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Transcript : Kymera Therapeutics, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-14-2022 08
